Table 3.

Adjusted effect of pravastatin on clinical outcomes by CKD status and diabetic statusa

No CKD NondiabeticCKD NondiabeticNo CKD DiabeticCKD Diabetic
N141944099873571
Coronary heart disease death, nonfatal MI, CABG, or PTCA0.76 (0.70 to 0.82)0.77 (0.68 to 0.87)0.73 (0.57 to 0.94)0.75 (0.57 to 0.98)
Coronary heart disease death, nonfatal MI, CABG, PTCA, or stroke0.77 (0.71 to 0.83)0.80 (0.71 to 0.90)0.68 (0.54 to 0.86)0.79 (0.62 to 1.03)
All-cause mortality0.71 (0.63 to 0.81)0.97 (0.82 to 1.15)0.87 (0.61 to 1.23)0.98 (0.69 to 1.39)
Coronary heart disease death or nonfatal MI0.68 (0.61 to 0.76)0.85 (0.73 to 1.00)0.79 (0.57 to 1.09)0.84 (0.60 to 1.18)
CABG or PTCA0.81 (0.72 to 0.90)0.72 (0.61 to 0.86)0.58 (0.41 to 0.82)0.69 (0.47 to 1.01)
Any stroke0.77 (0.61 to 0.96)0.96 (0.71 to 1.30)0.48 (0.28 to 0.82)1.12 (0.63 to 1.97)
  • a Values are for hazard ratios with 95% confidence intervals in parentheses. Hazard ratios have been adjusted for age; systolic BP; HDL cholesterol; LDL cholesterol; triglycerides; an indicator for trial (CARE, LIPID, or WOSCOPS); current smoking status; history of stroke; history of coronary disease; insulin dependence; and baseline use of aspirin, β blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers. Median follow-up period was 64 mo.